Log in

NASDAQ:XENEXenon Pharmaceuticals Stock Price, Forecast & News

$11.20
-0.10 (-0.88 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.82
Now: $11.20
$11.68
50-Day Range
$10.93
MA: $12.42
$13.35
52-Week Range
$7.00
Now: $11.20
$18.45
Volume245,916 shs
Average Volume105,982 shs
Market Capitalization$391.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Read More
Xenon Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.83 million
Book Value$2.99 per share

Profitability

Net Income$-41,600,000.00
Net Margins-102.25%

Miscellaneous

Employees89
Market Cap$391.66 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$11.20
-0.10 (-0.88 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

How has Xenon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XENE shares have decreased by 11.9% and is now trading at $11.20.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Xenon Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xenon Pharmaceuticals
.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Xenon Pharmaceuticals
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) released its quarterly earnings data on Thursday, May, 21st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.32) by $0.10. The biopharmaceutical company had revenue of $7.08 million for the quarter, compared to analysts' expectations of $7.50 million. Xenon Pharmaceuticals had a negative return on equity of 25.27% and a negative net margin of 102.25%.
View Xenon Pharmaceuticals' earnings history
.

What price target have analysts set for XENE?

5 Wall Street analysts have issued 1 year price targets for Xenon Pharmaceuticals' stock. Their forecasts range from $22.00 to $25.00. On average, they expect Xenon Pharmaceuticals' share price to reach $23.25 in the next year. This suggests a possible upside of 107.6% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals
.

Has Xenon Pharmaceuticals been receiving favorable news coverage?

News headlines about XENE stock have trended extremely negative on Sunday, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of -4.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Xenon Pharmaceuticals
.

Who are some of Xenon Pharmaceuticals' key competitors?

What other stocks do shareholders of Xenon Pharmaceuticals own?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:
  • Simon Neil Pimstone, Chief Executive Officer & Director
  • Ian C. Mortimer, President, Chief Financial Officer & Secretary
  • Ernesto Aycardi, Chief Medical Officer
  • Robin Sherrington, Executive VP-Business & Corporate Development
  • Charles J. Cohen, Vice President-Biological Sciences

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Swiss National Bank (0.18%), Alps Advisors Inc. (0.14%), Virtus ETF Advisers LLC (0.08%), Quantitative Systematic Strategies LLC (0.03%) and UBS Group AG (0.01%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals
.

Which major investors are buying Xenon Pharmaceuticals stock?

XENE stock was acquired by a variety of institutional investors in the last quarter, including Swiss National Bank, Alps Advisors Inc., Virtus ETF Advisers LLC, Quantitative Systematic Strategies LLC, and UBS Group AG.
View insider buying and selling activity for Xenon Pharmaceuticals
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $11.20.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $391.66 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.